MarketLens
Sign Up

What Does Sarepta Therapeutics' Director Share Sale Signal to Investors

8 months ago
SHARE THIS ON:

What Does Sarepta Therapeutics' Director Share Sale Signal to Investors

Exclusive Content for Pro Members

Pro members only. Upgrade to access this article, premium analysis, and stock recommendations.

SHARE THIS ON:

Related Articles

Category

You may also like

Stock News•2 months ago

LivaNova Director Sells 1,650 Shares for $131,500

A LivaNova director sold 1,650 shares for ~$131,500, equal to 17% of their direct stake before the filing. The transaction reduces the director's direct holdings, with no stated catalyst.
Stock News•2 months ago

Sarepta Therapeutics Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Sarepta Therapeutics, Inc. - SRPT

Kahn Swick & Foti launched an investigation into Sarepta Therapeutics' officers and directors, following the company's Elevidys Duchenne muscular dystrophy therapy. The probe could pressure SRPT share...
Stock News•4 months ago

What This PTC Therapeutics Insider Sale Means as Product Revenue Hit $226 Million

PTC Therapeutics product revenue reached $226M, while an insider sold shares at ~$90.25, generating $222K from option exercises. The sale represented 4% of the insider's direct holdings.

Breaking News

View All →

Top Headlines

View More →
Stock News•20 minutes ago

Microsoft had rallied back to record highs. Then came the election and Outlook outage

Stock News•34 minutes ago

Palo Alto Networks (PANW) Q1 Earnings and Revenues Top Estimates

Stock News•35 minutes ago

Elon Musk says ousting Jensen Huang is like ‘kicking Michael Jordan off your team'

Stock News•43 minutes ago

Nvidia Q3: Hasn't Been This Cheap In A Decade

Stock News•46 minutes ago

Palo Alto Networks: Accelerating Growth and a $4.5 Billion Bet on the Future of Cybersecurity